CN108289929A - 用于治疗神经退行性障碍的同源异型蛋白 - Google Patents

用于治疗神经退行性障碍的同源异型蛋白 Download PDF

Info

Publication number
CN108289929A
CN108289929A CN201680059070.1A CN201680059070A CN108289929A CN 108289929 A CN108289929 A CN 108289929A CN 201680059070 A CN201680059070 A CN 201680059070A CN 108289929 A CN108289929 A CN 108289929A
Authority
CN
China
Prior art keywords
homeoprotein
dna
neurons
disease
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680059070.1A
Other languages
English (en)
Chinese (zh)
Inventor
阿兰·浦勒昌斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
College de France
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
College de France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, College de France filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN108289929A publication Critical patent/CN108289929A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680059070.1A 2015-09-23 2016-09-23 用于治疗神经退行性障碍的同源异型蛋白 Pending CN108289929A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482.9 2015-09-23
EP15306482 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
CN108289929A true CN108289929A (zh) 2018-07-17

Family

ID=54207439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680059070.1A Pending CN108289929A (zh) 2015-09-23 2016-09-23 用于治疗神经退行性障碍的同源异型蛋白

Country Status (7)

Country Link
US (2) US20190247461A1 (https=)
EP (2) EP3352777B1 (https=)
JP (1) JP6860575B2 (https=)
CN (1) CN108289929A (https=)
ES (2) ES2895154T3 (https=)
PL (2) PL3960195T3 (https=)
WO (1) WO2017071889A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120676931A (zh) 2023-01-13 2025-09-19 布瑞恩维公司 Engrailed蛋白的稳定水性组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104030A2 (fr) * 2003-05-20 2004-12-02 Centre National De La Recherche Scientifique Peptides modulateurs de l'activite du facteur de transcription engrailed
CN101675341A (zh) * 2006-12-19 2010-03-17 萨里大学 癌症的生物标志物
CN102549433A (zh) * 2009-07-13 2012-07-04 萨里大学 治疗肽、多肽和核酸序列
WO2013128239A1 (en) * 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104030A2 (fr) * 2003-05-20 2004-12-02 Centre National De La Recherche Scientifique Peptides modulateurs de l'activite du facteur de transcription engrailed
CN101675341A (zh) * 2006-12-19 2010-03-17 萨里大学 癌症的生物标志物
CN102549433A (zh) * 2009-07-13 2012-07-04 萨里大学 治疗肽、多肽和核酸序列
WO2013128239A1 (en) * 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALAIN PROCHIANTZ ET AL: "Postnatal signalling with homeoprotein transcription factors", 《PHILOS TRANS R SOC LOND B BIOL SCI》 *
DANIEL ALVAREZ-FISCHER ET AL: "Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults", 《NATURE NEUROSCIENCE》 *
RAOUL TORERO IBAD ET AL: "Otx2 promotes the survival of damaged adult retinal ganglion cells and protects against excitotoxic loss of visual acuity in vivo", 《THE JOURNAL OF NEUROSCIENCE》 *

Also Published As

Publication number Publication date
EP3960195B1 (en) 2025-01-08
JP2018536697A (ja) 2018-12-13
PL3352777T3 (pl) 2022-02-07
EP3352777A1 (en) 2018-08-01
EP3960195A1 (en) 2022-03-02
WO2017071889A1 (en) 2017-05-04
CA2999209A1 (en) 2017-05-04
US20210379144A1 (en) 2021-12-09
ES3010130T3 (en) 2025-04-01
US20190247461A1 (en) 2019-08-15
PL3960195T3 (pl) 2025-06-09
ES2895154T3 (es) 2022-02-17
JP6860575B2 (ja) 2021-04-14
EP3352777B1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
Meriin et al. Role of molecular chaperones in neurodegenerative disorders
Carty et al. SARM: From immune regulator to cell executioner
Shah et al. Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration
Xu et al. Melatonin delays photoreceptor degeneration in a mouse model of autosomal recessive retinitis pigmentosa
Wang et al. Emerging molecular therapeutic targets for spinal cord injury
Qiu et al. AAV8-mediated angiotensin-converting enzyme 2 gene delivery prevents experimental autoimmune uveitis by regulating MAPK, NF-κB and STAT3 pathways
CN109937053B (zh) 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物
Chánez-Paredes et al. The Arp2/3 inhibitory protein arpin is required for intestinal epithelial barrier integrity
Zhang et al. Thioredoxin‐interacting protein (TXNIP) knockdown protects against sepsis‐induced brain injury and cognitive decline in mice by suppressing oxidative stress and neuroinflammation
Akaiwa et al. Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma
Guijarro-Belmar et al. The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′, 5′-monophosphate (Epac) for central nervous system trauma
US20130197069A1 (en) Methods for treating stress induced emotional disorders
Jiao et al. Minocycline protects retinal ganglion cells after optic nerve crush injury in mice by delaying autophagy and upregulating nuclear factor-κB2
Xu et al. Beneficial effects of local profound hypothermia and the possible mechanism after experimental spinal cord injury in rats
CN115006534A (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
US20210379144A1 (en) Homeoproteins for use in the treatment of neurodegenerative disorders
Ni et al. Neuroimmune regulation of IFITM3 via γ-secretase in astrocytes during cerebral ischemia-reperfusion
Lu et al. Znhit1 regulates p21Cip1 to control mouse lens differentiation
CA2999209C (en) Homeoproteins for use in the treatment of neurodegenerative disorders
US11083708B2 (en) Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling
Murphy et al. Endogenous polysialylated neural cell adhesion molecule enhances the survival of retinal ganglion cells
US20090104175A1 (en) Use of caspases for the preparation of medicaments
Liu et al. Muscarinic acetylcholine receptor antagonist darifenacin protects against pulmonary fibrosis through ERK/NF-κB/miR-21 pathway
WO2023279067A1 (en) Targeting piezo1 to treat inherited and age-related macular degenerations
US20230390283A1 (en) Uses of chk2 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180717

RJ01 Rejection of invention patent application after publication